-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FsaKwDNZKyTA546bWqu7/o+a4LFFMbsfGQNxb3hgDD0bzKbsejsllTUTZnZg7eQA 9qYBK3YSFjAITa/iHFa5Nw== 0001454982-09-000062.txt : 20090306 0001454982-09-000062.hdr.sgml : 20090306 20090306201836 ACCESSION NUMBER: 0001454982-09-000062 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20090304 FILED AS OF DATE: 20090306 DATE AS OF CHANGE: 20090306 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: EBERHARD CRAIG A CENTRAL INDEX KEY: 0001236393 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19700 FILM NUMBER: 09664647 BUSINESS ADDRESS: BUSINESS PHONE: 8585522200 MAIL ADDRESS: STREET 1: AMYLIN PHARMACEUTICALS INC STREET 2: 9360 TOWNE CENTRE DR CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMYLIN PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000881464 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330266089 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9360 TOWNE CENTRE DR STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 6195522200 MAIL ADDRESS: STREET 1: 9360 TOWNE CENTRE DR STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 edgardoc.xml PRIMARY DOCUMENT X0303 4 2009-03-04 0 0000881464 AMYLIN PHARMACEUTICALS INC AMLN 0001236393 EBERHARD CRAIG A 9360 TOWNE CENTRE DR SAN DIEGO CA 92121 0 1 0 0 VP Sales Common Stock 2009-03-04 4 A 0 2550 0 A 3455 I by ESOP Common Stock 24464 D Incentive Stock Option (right to buy) 9.02 2009-03-04 4 A 0 4687 0 A 2016-03-04 Common Stock 4687 4687 D Non-Qualified Stock Option (right to buy) 9.02 2009-03-04 4 A 0 10000 0 A 2016-03-04 Common Stock 10000 10000 D Non-Qualified Stock Option (right to buy) 9.02 2009-03-04 4 A 0 10313 0 A 2016-03-04 Common Stock 10313 20313 D These shares fully vest four years from the date of the reporting person's participation in the ESOP in four equal annual installments and are generally distributed upon termination of employment. 25% of shares vest one year from date of grant and the remainder vest monthly over the next three years becoming fully vested four years from date of grant. These performance-based options fully vest only if Amylin's drug candidate exenatide once weekly is approved for commercial use by year-end 2010. If this business objective is not attained by December 31, 2010, the options will be forfeited. By: /s/Lloyd A. Rowland, Attorney-in-Fact For: Craig A. Eberhard 2009-03-06 -----END PRIVACY-ENHANCED MESSAGE-----